Mylan Pharmaceuticals announced on Tuesday a voluntary recall for a batch of insulin glargine injection pens, used by some people with diabetes, due to missing labels.
Unlabeled pens could lead patients to take the incorrect dosage of insulin which could cause serious health problems.
The unlabeled pens are 100 units/mL, 3 mL insulin glargine-yfgn injection pens.
The recall is only for the unbranded pens, not the branded Semglee pens that are functionally the same.
Consumers should look out for batch number BF21002895 on the cartons of five pens offered by retailers.
The bad batch was distributed in the U.S. on April 4 and 5.
Retailers and distributors have already been notified and should have pulled the pens off shelves by now.
No adverse effects have yet been reported.
Anyone who has an unlabeled pen can report it at 1-877-643-8438 and return the product for a refund or replacement.
